Gemtuzumab ozogamicin in non-acute promyelocytic acute myeloid leukemia. - Wikidata - wikimedia - TriplyDB

Gemtuzumab ozogamicin in non-acute promyelocytic acute myeloid leukemia.

Gemtuzumab ozogamicin in non-acute promyelocytic acute myeloid leukemia.

http://www.wikidata.org/entity/Q37910260

about

Phase II trial of vorinostat and gemtuzumab ozogamicin as induction and post-remission therapy in older adults with previously untreated acute myeloid leukemia.Biological rationale for the design of polymeric anti-cancer nanomedicines.Antibody-drug conjugates - a perfect synergy.Gemtuzumab ozogamicin in acute myeloid leukemia.

P2860

Q35930622-3E12B190-FF96-423E-A4A9-E897FD4A5D20 Q36160333-73688351-DBE4-44A2-9404-51C5F032415C Q38014923-BE04B3F5-4938-402C-A263-202B7646BE5F Q38728718-5FF9DA33-8DF7-43C2-A360-F680C990AF06

P2860

Gemtuzumab ozogamicin in non-acute promyelocytic acute myeloid leukemia.

http://www.wikidata.org/entity/Q37910260

description

article científic

@ca

article scientifique

@fr

articol științific

@ro

articolo scientifico

@it

artigo científico

@gl

artigo científico

@pt

artigo científico

@pt-br

artikel ilmiah

@id

artikull shkencor

@sq

artículo científico

@es

name

Gemtuzumab ozogamicin in non-acute promyelocytic acute myeloid leukemia.

@en

Gemtuzumab ozogamicin in non-acute promyelocytic acute myeloid leukemia.

@nl

type

label

Gemtuzumab ozogamicin in non-acute promyelocytic acute myeloid leukemia.

@en

Gemtuzumab ozogamicin in non-acute promyelocytic acute myeloid leukemia.

@nl

prefLabel

Gemtuzumab ozogamicin in non-acute promyelocytic acute myeloid leukemia.

@en

Gemtuzumab ozogamicin in non-acute promyelocytic acute myeloid leukemia.

@nl

P1433

Q37910260-D7C3C7FC-F539-40B9-8FF5-0F741265BFC3

P1476

Q37910260-56DD9D7F-514E-4853-B2B7-C2FF21541795

P2093

Q37910260-133D8E87-D27A-4F2D-93C0-8ABD10FE27C8

Q37910260-C4464732-8136-40B2-A072-55E657351AF8

P2860

Q37910260-037D0CBB-5B01-4845-8281-64C679EF7352

Q37910260-060B5EC7-7918-4738-88F4-41A280B7FD13

Q37910260-09385A95-F58B-4607-AFA5-BA2313BC8D94

Q37910260-0BF98D95-0F1C-4858-95BD-EB7976E4B3EB

Q37910260-0E8514B6-A6DF-4BFF-85CD-5EBFB08DA53B

Q37910260-0F4A3D2C-7AC6-4ADA-A254-F239B8D37520

Q37910260-151FC855-61D8-4ED8-A33D-7419C3867CFC

Q37910260-19950ED5-C84F-4BA9-9890-522DCFFC7AB6

Q37910260-1E32D98F-A328-46F8-A3AB-359212A8D820

Q37910260-2184070E-87BA-48BB-B1DF-2F72CA9279D8

P304

Q37910260-DD7F6ED0-F1B9-4529-940B-BEA94C4C1162

P31

Q37910260-72AC5DE8-F2C6-4A04-AC33-195BB668769F

P356

Q37910260-61071052-166D-4254-81F0-E91A49431108

P407

Q37910260-334B16E2-040D-40C3-9A5F-0969F6B45EC2

P433

Q37910260-E420F9C4-49A2-4623-92CE-B2CEA2D61261

P478

Q37910260-667857FE-3EE4-4740-B582-B3EA36272C36

P577

Q37910260-15722F49-F36E-44A4-B5D8-19CBDB067734

P698

Q37910260-7459BA36-0927-4D8E-BBFE-113E7FD4493D

P921

Q37910260-22C4DDCD-2470-4538-B0F6-8FCB30F7FEC5

P356

14712598.2011.604630

P1433

Expert Opinion on Biological Therapy

P1476

Gemtuzumab ozogamicin in non-acute promyelocytic acute myeloid leukemia.

@en

P2093

Marie-Luise Hütter

http://www.w3.org/2001/XMLSchema#string

Richard F Schlenk

http://www.w3.org/2001/XMLSchema#string

P2860

CD33 expression and P-glycoprotein-mediated drug efflux inversely correlate and predict clinical outcome in patients with acute myeloid leukemia treated with gemtuzumab ozogamicin monotherapy

Prior gemtuzumab ozogamicin exposure significantly increases the risk of veno-occlusive disease in patients who undergo myeloablative allogeneic stem cell transplantation

Siglecs and their roles in the immune system

Diagnosis and management of acute myeloid leukemia in adults: recommendations from an international expert panel, on behalf of the European LeukemiaNet

Antibody-targeted chemotherapy of older patients with acute myeloid leukemia in first relapse using Mylotarg (gemtuzumab ozogamicin).

Gemtuzumab ozogamicin for relapsed and refractory acute myeloid leukemia and myeloid sarcomas.

Final report of the efficacy and safety of gemtuzumab ozogamicin (Mylotarg) in patients with CD33-positive acute myeloid leukemia in first recurrence.

High efficacy and safety profile of fractionated doses of Mylotarg as induction therapy in patients with relapsed acute myeloblastic leukemia: a prospective study of the alfa group.

Age and acute myeloid leukemia: real world data on decision to treat and outcomes from the Swedish Acute Leukemia Registry.

A Phase 2 study of combination therapy with arsenic trioxide and gemtuzumab ozogamicin in patients with myelodysplastic syndromes or secondary acute myeloid leukemia.

P304

1369-1380

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1517/14712598.2011.604630

http://www.w3.org/2001/XMLSchema#string

P407

P433

10

http://www.w3.org/2001/XMLSchema#string

P478

11

http://www.w3.org/2001/XMLSchema#string

P577

2011-08-03T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

21810061

http://www.w3.org/2001/XMLSchema#string

P921